A Label-Free Multi-Omic Study of a Glucosylceramide Inhibitor Effects on Obesity — ASN Events

A Label-Free Multi-Omic Study of a Glucosylceramide Inhibitor Effects on Obesity (#113)

Lee Gethings 1 , John Shockcor 2 , Robert Beynon 3 , Johannes Aerts 4 , Christopher Buck 5
  1. Waters Corporation, Manchester, UK
  2. Waters Corporation, Milford, MA, USA
  3. Institute of Integrative Biology, University of Liverpool, Liverpool, UK
  4. Dept of Medical Biochemistry, University of Amsterdam, Amsterdam, Netherlands
  5. Waters Australia, Burnside, VIC, Australia

Obesity is one of the risk-factors associated with metabolic syndrome, causing excess body fat to be accumulated to the extent that it adversely affects health and life expectancy. It has previously been demonstrated that glucosylceramides play a crucial part in such metabolic syndromes. The manipulation of the function of glucosylceramides with small molecule drug compounds within mouse models has shown that symptoms can be negated. Knowledge relating to the proteome, metabolome and lipidome during development is still to be fully explored. The work presented here is to provide a multi-omic analysis of protein and lipid liver extracts from control and obese mouse models undergoing treatment to prevent or revert obesity.

  1. Aerts et al. Pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity. Diabetes. 2007, 56, 1341-1349.
  2. Bligh et al. A rapid method of total lipid extraction and purification. Can J Biochem., 1959, 37, 911-917.
  3. Li et al. Database searching and accounting of multiplexed precursor and product ion spectra from the data independent analysis of simple and complex peptide mixtures. Proteomics. 2009, 9, 1696-1719.
  4. Richardson et al. A probabilistic framework for peptide and protein quantification from data-dependent and data-independent LC-MS proteomics experiments. OMICS. 2012, 16, 468-482.